Literature DB >> 19298095

VHA pharmacy use in veterans with Medicare drug coverage.

Robert O Morgan1, Laura A Petersen, Jennifer C Hasche, Jessica A Davila, Margaret M Byrne, Nora I Osemene, Iris I Wei, Michael L Johnson.   

Abstract

OBJECTIVE: To determine how Medicare benefits affect veterans' use of Veterans Health Administration (VHA) pharmacy services. STUDY
DESIGN: Retrospective analysis of veterans dually enrolled in the Veterans Health Administration and Medicare healthcare systems.
METHODS: We used VHA and Medicare administrative data for calendar year 2002 to examine the effect of Medicare HMO pharmacy benefit levels on VHA pharmacy use.
RESULTS: In 2002, 64% of the VHA and Medicare dually enrolled veterans in our study sample received medications from the VHA. Use of VHA pharmacy services varied monotonically by the level of pharmacy benefits among Medicare HMO enrollees, with veterans enrolled in plans with both low and high pharmacy benefit levels significantly less likely to use VHA pharmacy services than veterans in plans with no pharmacy benefits (odds ratios = .83 and .53, respectively, versus plans with no benefits). Among VHA pharmacy users, enrollment in plans with high levels of benefits was associated with significantly lower annual pharmacy costs than enrollment in plans with no benefits or enrollment in traditional Medicare.
CONCLUSIONS: Our findings indicate that non-VHA pharmacy benefits affect both the likelihood and magnitude of VHA pharmacy use. This suggests that Medicare pharmacy coverage (Part D) may significantly reduce the demand for VHA pharmacy services, particularly in geographic regions previously underserved by Medicare managed care plans.

Mesh:

Year:  2009        PMID: 19298095

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  13 in total

1.  Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality.

Authors:  Aaron P Thrift; Yamini Natarajan; Yan Liu; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-06       Impact factor: 11.382

2.  Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

Authors:  Dang M Nguyen; Peter Richardson; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2010-02-23       Impact factor: 22.682

3.  Dual-System Use and Intermediate Health Outcomes among Veterans Enrolled in Medicare Advantage Plans.

Authors:  Alicia L Cooper; Lan Jiang; Jean Yoon; Mary E Charlton; Ira B Wilson; Vincent Mor; Kenneth W Kizer; Amal N Trivedi
Journal:  Health Serv Res       Date:  2015-04-06       Impact factor: 3.402

4.  Impact of Dual Use of Department of Veterans Affairs and Medicare Part D Drug Benefits on Potentially Unsafe Opioid Use.

Authors:  Walid F Gellad; Joshua M Thorpe; Xinhua Zhao; Carolyn T Thorpe; Florentina E Sileanu; John P Cashy; Jennifer A Hale; Maria K Mor; Thomas R Radomski; Leslie R M Hausmann; Julie M Donohue; Adam J Gordon; Katie J Suda; Kevin T Stroupe; Joseph T Hanlon; Francesca E Cunningham; Chester B Good; Michael J Fine
Journal:  Am J Public Health       Date:  2017-12-21       Impact factor: 9.308

5.  Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

Authors:  Dang M Nguyen; Jim Schwartz; Peter Richardson; Hashem B El-Serag
Journal:  Dig Dis Sci       Date:  2010-04-16       Impact factor: 3.199

6.  Limited Osteoporosis Screening Effectiveness Due to Low Treatment Rates in a National Sample of Older Men.

Authors:  Cathleen S Colón-Emeric; Carl F Pieper; Courtney H Van Houtven; Janet M Grubber; Kenneth W Lyles; Joanne Lafleur; Robert A Adler
Journal:  Mayo Clin Proc       Date:  2018-12       Impact factor: 7.616

7.  Use of outpatient care in Veterans Health Administration and Medicare among veterans receiving primary care in community-based and hospital outpatient clinics.

Authors:  Chuan-Fen Liu; Michael Chapko; Chris L Bryson; James F Burgess; John C Fortney; Mark Perkins; Nancy D Sharp; Matthew L Maciejewski
Journal:  Health Serv Res       Date:  2010-10       Impact factor: 3.402

8.  Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.

Authors:  Derek Lin; Jennifer R Kramer; David Ramsey; Abeer Alsarraj; Gordana Verstovsek; Massimo Rugge; Paola Parente; David Y Graham; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2013-07-16       Impact factor: 10.864

9.  Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit.

Authors:  J K Hou; J R Kramer; P Richardson; S Sansgiry; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2012-10-14       Impact factor: 8.171

10.  Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis.

Authors:  Nabeel Khan; Ali Abbas; Alice Williamson; Luis Balart
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.